Sino Biopharmaceutical Limited — Cyborg Score 7/10
Strong
Pharmaceuticals & Biotechnology
Strategic Profile
The company offers a comprehensive oncology portfolio including anlotinib, penpulimab, and multiple targeted therapies with branded products like Focus V, Annike, and Yilishu. This diversified therapeutic approach combined with both Western and modernized Chinese medicine capabilities provides competitive differentiation in a large and growing market.
Cyborg Score Rationale
Recent half-year earnings of 0.21 HKD per share exceeded estimates by 56.67%, demonstrating strong operational performance. The company maintains significant revenue generation and operates as a leading innovation-driven pharmaceutical conglomerate, though exposure to regulatory and pricing pressures in China creates some headwinds.
Top Insights
Half-year 2025 revenue of 19.26 billion HKD exceeded estimates of 19.18 billion HKD, demonstrating consistent market demand
Significant earnings surprise of 56.67% in recent half-year results suggests operational efficiency gains
Portfolio spans high-growth oncology segment with multiple branded cancer therapeutics addressing major disease areas
Covered by 43 analysts with 24 submitting formal revenue/earnings estimates, indicating institutional interest
Named Competitors
Luokang Bio — Chinese oncology and specialty pharmaceuticals
BeiGene — China-based oncology and immunotherapy innovator
Zai Lab — Innovative pharmaceutical company in China